The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.
Patients with chronic lymphocytic leukemia (CLL) who have a 17p deletion (del[17p]) and failed at least one prior therapy now have another option on the table. The FDA approved Venclexta (venetoclax), a BCL-2 inhibitor, after nearly 80 percent of patients with relapsed/refractory del(17p) CLL elicited responses.
“These patients now have a new, targeted therapy that inhibits a protein involved in keeping tumor cells alive,” said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “For certain patients with CLL who have not had favorable outcomes with other therapies, Venclexta may provide a new option for their specific condition.”
The open-label, single-arm, multicenter M13-982 study included 106 patients with relapsed/refractory del(17p) CLL. The median age was 67 years and patients had received a median of 2.5 prior regimens. Many of the patients were refractory to Fludara and Treanda therapy.
Patients received Venclexta once daily with a weekly dose ramp-up schedule (20, 50, 100, 200, 400 mg) over a period of five weeks with tumor lysis syndrome prophylaxis. Patients were treated with 400 mg of Venclexta daily dosed continuously until disease progression or discontinuation. As of the interim data cutoff (April 30, 2015), the median time on study was 12.1 months.
Overall, 79.4 percent of the 106 patients evaluated in the clinical trial responded to Venclexta monotherapy according to the independent review committee evaluation, including eight patients (7.5 percent) with a complete remission (CR) or a CR with incomplete marrow recovery (CRi). Of 45 patients evaluated for minimal residual disease (MRD), 18 attained MRD-negative status in their peripheral blood.
When presenting the data at the 2015 ASH Annual Meeting, lead study author Stephan Stilgenbauer of the University of Ulm, Germany, said one of the most noteworthy outcomes of the study was the impact of Venclexta on the change in absolute lymphocyte count among participants. Only four of the 87 patients with baseline lymphocytosis did not normalize to less than 4x10.9 In addition, the median time to normalization was 22 days.
The median time to first response was 0.8 months and the median time to CR/CRi was 8.2 months. At 12 months' median follow-up, the median duration of response had not been reached.
In the realm of adverse events (AEs), Stilgenbauer said patients treated with Venclexta during the trial experienced AEs that were comparable to or less prevalent than those experienced by individuals receiving frontline chemotherapy.
Ninety-six percent of 103 evaluable patients experienced a treatment-emergent AE of any grade, including 76 percent with grade 3/4 events. The most common all-grade AEs included neutropenia (43 percent), diarrhea (29 percent), and nausea (29 percent).
Infections occurred in a total of 77 patients (72 percent), but there were only 16 patients (15 percent) who had upper respiratory tract infections of any grade including only two patients (2 percent) with grade 3/4 infections. Stilgenbauer said it was “reassuring” that respiratory infections were uncommon and that the overall infection rate was “lower than expected in this high-risk population.”
Simultaneous with the presentation of the phase 2 data at ASH, results of a phase 1 dose-escalation study of Venclexta among patients with CLL were published in The New England Journal of Medicine. In this study, the ORR was 79 percent with Venclexta among 116 patients treated during the study, including a CR in 20 percent of participants. The 15-month progression-free survival estimate for patients who received the highest dose of 400 mg per day was 69 percent.
All participants in that study had relapsed CLL and more than one-third were refractory to their last treatment, but the study was not restricted to patients with a 17p deletion.
Today’s regulatory approval follows an FDA breakthrough therapy designation granted to Venclexta in April 2015 for previously treated patients with del(17p) CLL.
“Up to half of people whose CLL progressed have 17p deletion, a genetic marker that makes the disease difficult-to-treat,” Sandra Horning, chief medical officer and head of Global Product Development at Genentech, which codevelops Venclexta along with AbbVie, said in statement. “Venclexta is the first approved medicine designed to trigger a natural process that helps cells self-destruct, and is a new way to help people who have been previously treated and have this high-risk form of the disease.”
Stilgenbauer S, Eichhorst BF, Schetelig JS, et al. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results of the pivotal international phase II study. Presented at: 57th American Society of Hematology Annual Meeting; Orlando, Florida; December 5-8, 2015. Abstract LBA6.
Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Eng J Med. doi:10.1056/NEJMoa1513257. 2016;374(4):311-322.